• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl cyanides
• Solvents and Organic Chemicals Organic Compounds cyanides/Cyanides

Recent Advances in the Study of 2,6-Dichlorophenylacetonitrile (CAS: 3215-64-3) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 2,6-Dichlorophenylacetonitrile (CAS: 3215-64-3) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This aromatic nitrile derivative serves as a key intermediate in the synthesis of various bioactive molecules, including agrochemicals, pharmaceuticals, and specialty chemicals. Recent studies have explored its potential as a building block for novel drug candidates, particularly in the development of kinase inhibitors and antimicrobial agents. The unique electronic and steric properties imparted by the dichloro substitution pattern make this compound a valuable scaffold for structure-activity relationship (SAR) studies.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2,6-Dichlorophenylacetonitrile in the design of selective JAK3 inhibitors. Researchers utilized this compound as a starting material to develop a series of novel pyrimidine derivatives showing promising immunosuppressive activity with reduced off-target effects compared to existing therapies. The study highlighted the compound's ability to serve as a versatile pharmacophore that can be readily modified to optimize drug-like properties. Molecular docking simulations revealed that derivatives containing the 2,6-dichlorophenyl moiety exhibited improved binding affinity to the JAK3 ATP-binding site while maintaining selectivity over other JAK isoforms.

In the field of antimicrobial research, 2,6-Dichlorophenylacetonitrile has shown potential as a precursor for novel antibacterial agents. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) described the synthesis and evaluation of a series of Schiff base derivatives incorporating this scaffold. These compounds demonstrated potent activity against multidrug-resistant Gram-positive bacteria, with minimum inhibitory concentrations (MICs) as low as 2 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) strains. The researchers attributed this activity to the compounds' ability to disrupt bacterial cell wall biosynthesis through inhibition of key enzymes in the peptidoglycan synthesis pathway.

From a synthetic chemistry perspective, recent advancements have focused on developing more efficient and sustainable routes to produce 2,6-Dichlorophenylacetonitrile. A 2023 Green Chemistry paper reported a novel continuous-flow synthesis method that reduces reaction times from hours to minutes while improving yield and purity. This innovation addresses previous challenges associated with the traditional batch synthesis methods, particularly in controlling side reactions and improving scalability. The new method employs catalytic C-H activation strategies, significantly reducing the environmental impact of the synthesis process.

The safety profile and toxicological characteristics of 2,6-Dichlorophenylacetonitrile have also been the subject of recent investigations. A comprehensive toxicology study published in Regulatory Toxicology and Pharmacology (2023) evaluated the compound's acute and subchronic toxicity in rodent models. The results indicated that while the compound shows moderate acute toxicity (oral LD50 of 320 mg/kg in rats), it does not exhibit significant genotoxic or carcinogenic potential at relevant exposure levels. These findings support its continued use in pharmaceutical development while emphasizing the need for proper handling procedures in industrial settings.

Looking forward, researchers are exploring the potential of 2,6-Dichlorophenylacetonitrile in emerging areas such as PROTAC (proteolysis targeting chimera) development and covalent inhibitor design. Its ability to serve as a linker or warhead in these advanced therapeutic modalities positions it as a valuable tool in modern drug discovery. As synthetic methodologies continue to evolve and our understanding of its biological interactions deepens, 2,6-Dichlorophenylacetonitrile is likely to remain an important compound in the chemical biology and pharmaceutical research landscape for years to come.

• 2856-63-5(2-Chlorobenzyl cyanide)
• 21316-51-8(2-(2,3,4,5,6-pentachlorophenyl)acetonitrile)
• 55405-39-5(1,4-Benzenediacetonitrile, 2,3,5,6-tetrachloro-)
• 3218-50-6(2-(2,5-dichlorophenyl)acetonitrile)
• 3218-45-9(2-(2,3-Dichlorophenyl)acetonitrile)
• 6306-60-1(2,4-Dichlorophenylacetonitrile)
• 70833-63-5((2,4,6-trichlorophenyl)acetonitrile)
• 4681-16-7(2-(2,3,5-Trichlorophenyl)acetonitrile)
• 3215-65-4(Benzeneacetonitrile,2,3,6-trichloro-)
• 56403-43-1(1,4-Benzenediacetonitrile, 2,5-dichloro-)